Biolife Sciences Stock Cash Per Share
| BLFE Stock | USD 0.0001 0.00 0.00% |
BioLife Sciences fundamentals help investors to digest information that contributes to BioLife Sciences' financial success or failures. It also enables traders to predict the movement of BioLife Pink Sheet. The fundamental analysis module provides a way to measure BioLife Sciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLife Sciences pink sheet.
BioLife |
BioLife Sciences Company Cash Per Share Analysis
BioLife Sciences' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, BioLife Sciences has a Cash Per Share of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Instruments & Supplies industry. The cash per share for all United States stocks is 100.0% higher than that of the company.
BioLife Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioLife Sciences' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioLife Sciences could also be used in its relative valuation, which is a method of valuing BioLife Sciences by comparing valuation metrics of similar companies.BioLife Sciences is currently under evaluation in cash per share category among its peers.
BioLife Fundamentals
| Current Valuation | 1.01 M | |||
| Price To Sales | 0 X | |||
| Net Income | (456.87 K) | |||
| Cash And Equivalents | 15.62 K | |||
| Total Debt | 398 K | |||
| Current Ratio | 0.07 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (106.55 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 0.0763 | |||
| Market Capitalization | 11.45 K |
About BioLife Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioLife Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLife Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLife Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BioLife Pink Sheet
BioLife Sciences financial ratios help investors to determine whether BioLife Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLife with respect to the benefits of owning BioLife Sciences security.